{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:38:42Z","timestamp":1790789922907,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400085"],"award-info":[{"award-number":["81400085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400088"],"award-info":[{"award-number":["81400088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570106"],"award-info":[{"award-number":["81570106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["14JCYBJC25400"],"award-info":[{"award-number":["14JCYBJC25400"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["15JCYBJC24300"],"award-info":[{"award-number":["15JCYBJC24300"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["15KG150"],"award-info":[{"award-number":["15KG150"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.biopha.2016.08.023","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T20:30:34Z","timestamp":1471379434000},"page":"1032-1037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["A novel histone deacetylase inhibitor Chidamide induces G0\/G1 arrest and apoptosis in myelodysplastic syndromes"],"prefix":"10.1016","volume":"83","author":[{"given":"Zhaoyun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2016.08.023_bib0005","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2016.08.023_bib0010","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2016.08.023_bib0015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2016.08.023_bib0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.biopha.2016.08.023_bib0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2010.01.011","article-title":"A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells","volume":"392","author":"Liu","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2016.08.023_bib0030","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2016.08.023_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1568011043352948","article-title":"Quantitative structure-activity relationship study of histone deacetylase inhibitors","volume":"4","author":"Xie","year":"2004","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.biopha.2016.08.023_bib0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","article-title":"Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells","volume":"68","author":"Zhou","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2016.08.023_bib0045","first-page":"1503","article-title":"Antitumor activity of Chidamide in hepatocellular carcinoma cell lines","volume":"5","author":"Wang","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2016.08.023_bib0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2016.08.023_bib0055","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells","volume":"443","author":"Gong","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2016.08.023_bib0060","first-page":"450","article-title":"[Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response]","volume":"23","author":"Xu","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.biopha.2016.08.023_bib0065","first-page":"963","article-title":"Transformation of myelodysplastic syndromes into acute myeloid leukemias","volume":"117","author":"Shi","year":"2004","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.biopha.2016.08.023_bib0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.leukres.2015.02.004","article-title":"Outcome of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML) treated with decitabine after azacitidine failure","volume":"39","author":"Harel","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2016.08.023_bib0075","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjh.13915","article-title":"Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group","volume":"172","author":"Cseh","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2016.08.023_bib0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2141.1993.tb03334.x","article-title":"Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome","volume":"85","author":"Nakagawa","year":"1993","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2016.08.023_bib0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/10428199709114174","article-title":"In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1","volume":"25","author":"Steube","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2016.08.023_bib0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L","article-title":"Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity","volume":"37","author":"Aubry","year":"1999","journal-title":"Cytometry"},{"key":"10.1016\/j.biopha.2016.08.023_bib0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4419-9967-2_13","article-title":"Epigenetic therapies in MDS and AML","volume":"754","author":"Griffiths","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biopha.2016.08.023_bib0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/cncr.29083","article-title":"Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia\/myelodysplastic syndrome: achievements and challenges","volume":"121","author":"L\u00fcbbert","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2016.08.023_bib0105","article-title":"Characterization of resistance to rhabdovirus and retrovirus infection in a human myeloid cell line","volume":"121455","author":"Boso","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2016.08.023_bib0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jchromb.2015.07.001","article-title":"Development and validation of a sensitive HPLC\u2013MS\/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application","volume":"1000","author":"Gu","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2016.08.023_bib0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcb.20179","article-title":"Regulation of histone deacetylase activities","volume":"93","author":"Sengupta","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2016.08.023_bib0120","doi-asserted-by":"crossref","first-page":"15540","DOI":"10.1073\/pnas.0607518103","article-title":"Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2016.08.023_bib0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1073\/pnas.0408732102","article-title":"Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors","volume":"102","author":"Ungerstedt","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2016.08.023_bib0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1091\/mbc.6.4.387","article-title":"Inhibition of cyclin-dependent kinases by p21","volume":"6","author":"Harper","year":"1995","journal-title":"Mol. Biol. Cell"},{"issue":"5067","key":"10.1016\/j.biopha.2016.08.023_bib0135","article-title":"Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21(CDKN1A)","volume":"5","author":"Mlynarczyk","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2016.08.023_bib0140","first-page":"2012","article-title":"NBM-HD-1: a novel histone deacetylase inhibitor with anticancer activity","volume":"781417","author":"Huang","year":"2012","journal-title":"Evid. Based Compl. Alternat. Med."},{"key":"10.1016\/j.biopha.2016.08.023_bib0145","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","article-title":"Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked","volume":"275","author":"Yang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.biopha.2016.08.023_bib0150","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2016.08.023_bib0155","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2016.08.023_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","article-title":"Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)","volume":"91","author":"Cashen","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2016.08.023_bib0165","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/leu.2013.325","article-title":"Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients","volume":"28","author":"Platzbecker","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2016.08.023_bib0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ajh.22198","article-title":"Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome","volume":"87","author":"Dimicoli","year":"2012","journal-title":"Am. J. Hematol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216308137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216308137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:43:39Z","timestamp":1776944619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216308137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":34,"alternative-id":["S0753332216308137"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2016.08.023","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel histone deacetylase inhibitor Chidamide induces G0\/G1 arrest and apoptosis in myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2016.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}